黏膜免疫抵抗由减毒重组仙台病毒引起的流感。

Mucosal immunity against influenza induced by attenuated recombinant Sendai virus.

机构信息

Department of Virology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.

出版信息

Expert Rev Vaccines. 2011 Oct;10(10):1393-5. doi: 10.1586/erv.11.123.

DOI:10.1586/erv.11.123

PMID:21988304

Abstract

Live-attenuated influenza vaccines (LAIVs) have been shown to be more immunogenic and capable of inducing a broader immune response than inactivated vaccine. However, use of LAIVs is still limited owing to the safety concerns. Le et al. generated an attenuated recombinant Sendai virus - GP42-H1 expressing the hemagglutinin (HA) gene of influenza A virus. The HA protein was expressed on the cell surface of CV-1 cells infected with GP42-H1. Intranasal immunization of mice with GP42-H1 induced HA-specific IgG and IgA antibodies in sera and mucosal sites without causing any disease symptoms. Immunized mice were also protected from lethal dose challenge of influenza A virus.

摘要

减毒活流感疫苗（LAIV）已被证明比灭活疫苗更具免疫原性，能够诱导更广泛的免疫反应。然而，由于安全性问题，LAIV 的使用仍然受到限制。Le 等人构建了一种表达甲型流感病毒血凝素（HA）基因的减毒重组仙台病毒-GP42-H1。HA 蛋白在感染 GP42-H1 的 CV-1 细胞表面表达。用 GP42-H1 经鼻腔免疫小鼠可诱导血清和黏膜部位产生 HA 特异性 IgG 和 IgA 抗体，而不引起任何疾病症状。免疫接种的小鼠还能抵抗致死剂量的甲型流感病毒攻击。